EGFR and head and neck squamous cell carcinoma: Mutations that trigger a constitutive activity of the EGFR receptor (mutations of the EGFR tyrosine kinase domain; expression of the EGFR variant III), or mutations that induce resistance to anti-EGFR antibodies (e.g., RAS genes mutations) are infrequent in HNSCC [8].